Press Releases

Laboratory for Advanced Medicine Announces New China CEO Position to Commercialize its Early Cancer Diagnostic for Liver and Colon Cancer Detection in Asia

June 15, 2020

Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of prominent business leader and Asia market expert, Samuel Tong, as Chief Executive Officer of Laboratory for Advanced Medicine's Chinese operations.

Read More

Laboratory for Advanced Medicine Appoints Former Ancestry Executive as Chief Operations Officer

February 18, 2020

Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of Benjamin Oyler as Chief Operating Officer. He will lead Laboratory for Advanced Medicine's global business operations.

Read More

Laboratory For Advanced Medicine Appoints Aarif Nakhooda as Chief Financial Officer

December 19, 2019

Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of Aarif Nakhooda as Chief Financial Officer. Mr. Nakhooda has more than 25 years of financial, commercial and operational experience with rapidly growing companies, including Amazon.

Read More

Laboratory For Advanced Medicine Adds High-Profile Cigna Health Senior Executive To Its Board of Directors

December 3, 2019

IRVINE, Calif., Dec. 3, 2019 /PRNewswire/ -- Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection test from a simple blood draw, today announced the appointment of Christopher DeRosa, MBA, an industry leader in medical insurance and reimbursement, to the company's Board of Directors.

Read More

Laboratory for Advanced Medicine Presents New Liver Cancer Test Data at The Liver Meeting 2019

November 12, 2019

IRVINE, Calif., Nov. 12, 2019 /PRNewswire/ -- Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced that it will be presenting new data supporting its methylation-based liver cancer diagnostic test at The Liver Meeting® 2019 hosted by the American Association for the Study of Liver Diseases (AASLD), taking place in Boston from Nov. 8-12. AASLD selected Laboratory for Advanced Medicine's

Read More

Laboratory for Advanced Medicine Appoints Kenneth Chahine, Ph.D., J.D., as Chief Executive Officer

November 7, 2019

Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of Kenneth Chahine, Ph.D., J.D., as Chief Executive Officer and board member. He will succeed Founder Shu Li, Ph.D., who will continue to serve as Chairman of the company's Board of Directors.

Read More

Laboratory for Advanced Medicine Appoints to its Board of Directors Dr. Alan List, President and CEO, Moffitt Cancer Center

October 23, 2019

IRVINE, Calif., Oct. 23, 2019 /PRNewswire/ -- Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of Alan List, M.D., an internationally recognized and respected oncologist, President and Chief Executive Officer at Moffitt Cancer Center, to the company's Board of Directors.

Read More

Laboratory for Advanced Medicine Receives FDA Breakthrough Device Designation for Liquid Biopsy Liver Cancer Detection Test

September 3, 2019

Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company with innovative technologies for the early diagnosis of cancer, today announced that its Liver Cancer detection test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA). The liquid biopsy blood test is designed to detect the presence of liver cancer, as early as Stage I, with high specificity and sensitivity.

Read More

Laboratory for Advanced Medicine Strengthens Hepatology Board with Addition of Three Distinguished Medical Doctors

August 8, 2019

Dr. Abou-Alfa, oncologist at Memorial Sloan Kettering; Dr. Gish, Medical Director of Hepatitis B Foundation; and Dr. Hoshida, Director of Translational Research in Liver Cancer at the University of Texas Southwestern Medical Center, bring liver cancer treatment expertise to company's board

Read More

LAM's IvyGene Liquid Biopsy Platform Demonstrates High Diagnostic Capabilities In New Cancer Indication

May 15, 2019

Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced positive results from a new study that evaluated DNA methylation-based marker panel for early diagnosis of nasopharyngeal carcinoma (NPC). The data appear in an online abstract as part of the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 to June 4, in Chicago.

Read More

LAM Announces New Data Demonstrating High Diagnostic Potential Of Cell-Free DNA Methylation Assay For Early, Non-Invasive Detection Of Liver, Breast And Colorectal Cancers At AACR 2019

March 31, 2019

IRVINE, Calif., March 31, 2019 -- Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced new data at the American Association for Cancer Research (AACR) Annual Meeting at the Georgia World Congress Center in Atlanta, Georgia. The data demonstrate LAM's proprietary IvyGene Tests possess the ability to detect liver cancer with 95% sensitivity and...

Read More

LAM to Present Data for Cell-Free DNA Methylation Assay for Non-Invasive Diagnosis of Liver, Breast and Colorectal Cancers at AACR Annual Meeting 2019

March 20, 2019

IRVINE, Calif., Mar. 20, 2019 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, announced today a poster presentation titled “Circulating Cell-Free DNA Methylation Assay: Towards Early Detection of Multiple Cancer Types” will be presented at the American Association for Cancer Research (AACR) Annual Meeting.

Read More

Laboratory for Advanced Medicine Announces New Data Demonstrating High Diagnostic Potential of DNA Methylation-Based Biomarkers for Early and Noninvasive Diagnosis of Breast Cancer at San Antonio Breast Cancer Symposium

December 7, 2018

IRVINE, Calif., Dec. 7, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced new data at the San Antonio Breast Cancer Symposium validating results from its discovery of biomarkers to accurately detect breast cancer.

Read More

LAM to Present Data Demonstrating Efficacy of DNA Methylation as Epigenetic Biomarkers for Non-Invasive Breast Cancer Detection at Upcoming San Antonio Breast Cancer Symposium

November 20, 2018

IRVINE, Calif., Nov. 20, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced the title of its abstract to be presented at the 2018 San Antonio Breast Cancer Symposium taking place Dec. 4 – 8 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. This presentation will include new data supporting the ability of LAM’s IvyGene Platform to detect blood

Read More

LAM Announces New Data Validating High Sensitivity and Specificity of DNA Methylation-Based Biomarkers for Noninvasive Diagnosis of Liver Cancer at SITC Meeting

November 6, 2018

IRVINE, Calif., Nov. 6, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced new data further validating results from its completed clinical study on liver cancer demonstrating the ability of LAM's novel DNA methylation-based biomarkers in detecting the presence of hepatocellular carcinoma (HCC) with 95% sensitivity and 97.5% specificity.

Read More

LAM Announces Presentation of DNA Methylation-Based Biomarker Data for Noninvasive Diagnosis of Hepatocellular Carcinoma at SITC 2018

October 23, 2018

IRVINE, Calif., Oct. 23, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced the title of its abstract to be presented at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting taking place Nov. 7-11, 2018 in Washington, D.C.

Read More

Laboratory for Advanced Medicine Appoints Jinjie Hu as Chief Regulatory Officer

July 12, 2018

IRVINE, Calif., July 12, 2018 /PRNewswire/ -- Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company focused on developing innovative technologies for the early diagnosis and intervention of cancers, today announced that the Company has recently appointed Dr. Jinjie Hu as its Chief Regulatory Officer. Dr. Hu has over a decade of experience working directly with the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER).

Read More

Laboratory for Advanced Medicine to Present at 2018 BIO International Convention

June 4, 2018

IRVINE, Calif., June 4, 2018 — Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company developing innovative technologies for the early diagnosis and intervention of cancers, today announced that Justin Li, General Manager and Vice President of Finance, will present at the 2018 BIO International Convention, taking place on…

Read More

Laboratory for Advanced Medicine Commercializes Non-Invasive, Artificial Intelligence-Based IvyGene Blood Test for Cancer Detection

May 30, 2018

IRVINE, Calif., May 30, 2018 — Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company developing innovative technologies for the early diagnosis and intervention of cancers, today announced the commercialization of its revolutionary, non-invasive and highly accurate IvyGene test. IvyGene is designed to detect DNA methylation patterns consistent with…

Read More

Laboratory for Advanced Medicine Appoints Richard Brand as Chief Financial Officer

May 17, 2018

IRVINE, Calif., May 17, 2018 — Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company focused on developing innovative technologies for the early diagnosis and intervention of cancers, today announced that the Company has appointed Richard Brand as its Chief Financial Officer, effective immediately. Mr. Brand has more than…

Read More

Firefighters Against Cancer and Exposures (FACES) Non-Profit Launches in Texas

May 14, 2018

IRVINE, Calif., March 14, 2018 — In an effort to help firefighters cover the high cost of cancer treatment as a result of the occupational risk of experiencing higher rates of certain types of cancer than the general U.S. population, Laboratory for Advanced Medicine (LAM) today announced the launch of…

Read More